150 related articles for article (PubMed ID: 24890168)
1. Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population.
Zhang X; Yang Y; Wang Q
Chin Med J (Engl); 2014; 127(11):2143-6. PubMed ID: 24890168
[TBL] [Abstract][Full Text] [Related]
2. Lycopene and soy isoflavones in the treatment of prostate cancer.
Vaishampayan U; Hussain M; Banerjee M; Seren S; Sarkar FH; Fontana J; Forman JD; Cher ML; Powell I; Pontes JE; Kucuk O
Nutr Cancer; 2007; 59(1):1-7. PubMed ID: 17927495
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
Clark PE; Hall MC; Borden LS; Miller AA; Hu JJ; Lee WR; Stindt D; D'Agostino R; Lovato J; Harmon M; Torti FM
Urology; 2006 Jun; 67(6):1257-61. PubMed ID: 16765186
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk.
Bunker CH; McDonald AC; Evans RW; de la Rosa N; Boumosleh JM; Patrick AL
Nutr Cancer; 2007; 57(2):130-7. PubMed ID: 17571945
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
7. Measurement of weekly prostate specific antigen levels in patients receiving pelvic radiotherapy for nonprostatic malignancies.
Vijayakumar S; Quadri SF; Sen S; Vaida F; Ignacio L; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):189-95. PubMed ID: 7536721
[TBL] [Abstract][Full Text] [Related]
8. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
Beer TM; Lemmon D; Lowe BA; Henner WD
Cancer; 2003 Mar; 97(5):1217-24. PubMed ID: 12599228
[TBL] [Abstract][Full Text] [Related]
9. Optimal measure of PSA kinetics to identify prostate cancer.
Benecchi L; Pieri AM; Destro Pastizzaro C; Potenzoni M
Urology; 2008 Mar; 71(3):390-4. PubMed ID: 18342170
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
11. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
Ansari MS; Gupta NP
Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
[TBL] [Abstract][Full Text] [Related]
12. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
Schwenke C; Ubrig B; Thürmann P; Eggersmann C; Roth S
J Urol; 2009 Mar; 181(3):1098-103. PubMed ID: 19150092
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Sella A; Sternberg CN; Skoneczna I; Kovel S
BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
[TBL] [Abstract][Full Text] [Related]
17. Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.
Paur I; Lilleby W; Bøhn SK; Hulander E; Klein W; Vlatkovic L; Axcrona K; Bolstad N; Bjøro T; Laake P; Taskén KA; Svindland A; Eri LM; Brennhovd B; Carlsen MH; Fosså SD; Smeland SS; Karlsen AS; Blomhoff R
Clin Nutr; 2017 Jun; 36(3):672-679. PubMed ID: 27406859
[TBL] [Abstract][Full Text] [Related]
18. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy.
Bates AT; Pickles T; Paltiel C
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):148-53. PubMed ID: 15850915
[TBL] [Abstract][Full Text] [Related]
19. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
Pantuck AJ; Leppert JT; Zomorodian N; Aronson W; Hong J; Barnard RJ; Seeram N; Liker H; Wang H; Elashoff R; Heber D; Aviram M; Ignarro L; Belldegrun A
Clin Cancer Res; 2006 Jul; 12(13):4018-26. PubMed ID: 16818701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
